Latest Santhera Pharmaceuticals Stories
Collaboration results from Duchenne community's draft guidance to FDA HACKENSACK, N.J., Nov.
LIESTAL, SWITZERLAND--(Marketwire - Oct. 10, 2008) - Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today the launch of CATENA(R) (idebenone) in Canada.
Santhera Pharmaceuticals has announced that Health Canada has approved SNT-MC17/idebenone, subject to certain conditions, for the treatment of Friedreich's Ataxia. Health Canada's decision is said to be the first marketing authorization worldwide for any Friedreich's Ataxia therapy.
Santhera Pharmaceuticals (SWX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich's Ataxia.
- The abrogation of a law by a higher authority; annulment.